NEW HAVEN, Conn. — August 13, 2025 — Leads & Copy — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has filed its 10-Q report, highlighting financial performance and outlook for 2025.
CEO Ilan Danieli noted revenue growth in both company divisions and improved gross margin, leading to better cash performance. The company anticipates completing the Change Healthcare loan repayment by year-end and expects to end the year with positive cash flow and a strong, debt-free balance sheet.
Q2-2025 revenues reached $5.7M, a 27% YoY increase from $4.4M in Q2-2024, and a 15% QoQ increase from Q1-2025. Pathology services revenue increased 18% from the prior quarter, while product revenues rose 23% (excluding $145K in Q1-2025 from a special pharmaceutical project).
Adjusted EBITDA improved by 87% YoY, from ($609K) to ($78K), driven by revenue growth and cost management. Cash used by operations decreased by 71% YoY, from $516K to $148K.
The Products Division saw momentum due to distributor network progress and a growing customer pipeline. Product revenues rebounded due to customers returning to full volume and new customer onboarding.
Pathology Services revenue increased by $0.75M (17%) from $4.25M in Q1-2025 to $5.0M in Q2-2025, driven by organic growth and sales team efforts. No substantial capital expenditures or significant laboratory staff additions are anticipated to support this growth.
Product’s division gross margins YoY were 44% in Q2-2025 and 50% in Q2-2024. Pathology Services division gross margins have increased YoY from 37% to 43%. Overall, the Company’s gross margin has increased YoY from 39% to 43%.
For inquiries, contact investors@precipiodx.com or +1-203-787-7888 Ext. 523.
Contact: investors@precipiodx.com, +1-203-787-7888 Ext. 523
Source: Precipio, Inc.
